Vaxcyte, Inc. (PCVX) has a negative trailing P/E of -10.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 40.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -9.38%, forward earnings yield 2.48%. PEG 0.12 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -5.4 | 0.00 | 3.01 | 0.00 | - |
| 2018 | -3.2 | -0.05 | -1.64 | 0.00 | - |
| 2019 | -2.0 | -0.03 | -0.93 | 0.00 | - |
| 2020 | -8.8 | 0.11 | 2.27 | 0.00 | - |
| 2021 | -12.3 | 0.35 | 4.35 | 0.00 | - |
| 2022 | -13.9 | -0.18 | 3.26 | 0.00 | - |
| 2023 | -15.2 | -0.75 | 4.92 | 0.00 | - |
| 2024 | -21.5 | 2.62 | 3.02 | 0.00 | - |
| 2025 | -8.2 | -0.17 | 2.34 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-4.83 | $0.00 | $-17.24M | - |
| 2018 | $-8.12 | $0.00 | $-29.49M | - |
| 2019 | $-14.10 | $0.00 | $-53.5M | - |
| 2020 | $-2.97 | $0.00 | $-87.82M | - |
| 2021 | $-1.93 | $0.00 | $-100.08M | - |
| 2022 | $-3.69 | $0.00 | $-239.64M | - |
| 2023 | $-4.14 | $0.00 | $-402.27M | - |
| 2024 | $-3.80 | $0.00 | $-463.93M | - |
| 2025 | $-5.63 | $0.00 | $-766.63M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-7.21 | $-9.25 – $-6.07 | $25M | $25M – $25M | 6 |
| 2027 | $-7.09 | $-10.20 – $-4.90 | $27.38M | $27.38M – $27.38M | 5 |
| 2028 | $-6.29 | $-10.38 – $-4.65 | $216.63M | $216.63M – $216.63M | 6 |
| 2029 | $1.55 | $1.55 – $1.55 | $1.53B | $1.53B – $1.53B | 4 |
| 2030 | $6.90 | $6.90 – $6.90 | $2.56B | $2.56B – $2.56B | 2 |
